EVGN Evogene Ltd Ord
$0.31
Evogene Ltd Ord Q3 F2026 Earnings Call Transcript
AI Conference Call Analysis
Sign in or subscribe to read.Conference Operator
Operator
Welcome to Evogen's third quarter 2026 results conference call. All participants are at present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded on November 19, 2026. Before we begin, I would like to caution that certain statements made during this conference call by Evergen's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events and Evergen Ltd. may from time to time make other statements regarding our outlook or expectations for future financial or operating results and or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRI, and other securities laws as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimate, intend, and potential, or words of similar meaning. We are using forward-looking statements in this presentation when we discussed our value drivers, commercialization efforts and timing, product development and launches, estimate market sizes and milestones, pipeline as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guaranteed of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the aftermath of the recent war between Israel and each of the terrorist groups Hamas and Hezbollah, Iran and other regional terrorist groups supported by Iran and any destabilization in Israel, neighboring terrorists or the Middle East region and those described in greater detail in Avagen's annual report on Form 20F and in other information, Avagen files and furnished with the Israel Securities Authorities and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors. Except as required by applicable securities law, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or development or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation or offer to purchase or subscribe for any securities of Evergen or the company, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in connection with any action. Contract commitment or relating thereto or to the securities of Avagen or the company. The trademarks include herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. With us on the line will be Nir Nimrodi, Evergen's Chairman of the Board of Directors, Ofer Haviv, President and CEO of Evergen, and Polina Ravzin, VP Finance of Evergen. Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.
Ofer Haviv
President and CEO
Good morning everyone and thank you for joining Evogen's third quarter 2026 analyst call. We appreciate your continued interest in the company and opportunity to update you on our progress. In the first part of today's call, I would like to focus on two of the company's internal development programs which demonstrate our strategy of leveraging our AI and the Global Development Platform Campus AI to create proprietary assets with significant commercial potential, fully owned and managed by Evogen. These activities are being pursued alongside the collaborative product discovery programs that the company is leading, which I have discussed in previous calls. The first program is Evogen's internal drug discovery program targeting acute graft The second comprises Agplanus fungicide discovery program targeting septoria, which focus on developing solutions with novel biological modes of action. I would like to emphasize that beyond the significant value associated With creating proprietary assets with meaningful economic potential, the results from these two programs also clearly demonstrate the strength of our platform, Campus AI. Following my remarks, I will hand over the discussion to Ms. Polina Ravzin, the company's VP Finance, who will focus on an analysis of the company's financial results for the first nine months of the year and the third quarter. We will then open the call for questions and answers. Let's begin with Avogen's internal drug discovery program. In October this year, we announced Acute GVHD as the target indication for our internal drug discovery program. Acute GVHD is a series of medical implications that can develop following hematopoietic The disease is characterized by an acute immune response in which immune cells from the donor attack the recipient's tissues. The unmet medical need is particularly significant among patients who do not respond to initial steroid treatment. According to published data, acute GVHD affects approximately 30% to 40% of transplant recipients, and mortality rates among patients with steroid refractory disease can reach as high as 50%. Despite the severity of the disease, second night treatment options remain limited, with wuxolitinib currently being the only approved treatment in this setting. Considering this significant unmet medical need, we identified an opportunity to develop a therapeutic approach based on small molecules designed to target a key biological pathway involved in the severe inflammatory response associated with the disease. In our view, the selection of this indication reflect a combination of a significant unmedical need and opportunity to apply campus AI discovery capabilities in an area where a new and differentiated therapeutic approach could potentially be developed. One of the most significant aspects of our announcement was the progress we achieved within a relatively short period of time. In just several months, utilizing campus AI, we generated a diverse series of novel small molecules candidates featuring diverse chemical scaffolds. These molecules are patentable and were designed with particularly synthetic feasibilities in mind. The molecules tested to date demonstrate several important characteristics and the most important is the higher biological potency reaching nanomolar concentrations. Additionally, they show predicted promising preliminary ADME and toxicology profiles, which are important parameters when evaluating The potential of a molecule to advance through the drug development process. We see this as a significant advantage because our objective is not simply to identify a molecule that demonstrates biological activity, but rather to generate candidates with a combination of properties that could support their advancement through the drug development process. Another important aspect of this program is the scientific and clinical guidance provided by two leading experts in the acute GVHD field, Dr. Khoury Kattler of Dana-Ferber Cancer Institute and Prof. Dr. Robert Zisser of University Medical Center of Freiburg. Their involvement supports our biological targets Our ability to generate, within a relatively short period, a series of novel molecules combining several desirable proprietories provides an important indication of our platform's ability to generate It is important to emphasize that we are still at an early discovery and development stage, and further optimization, characterization, and evaluations of these candidates will be required. Looking ahead, our focus is on generating novel molecular structures, synthesizing these molecules, identifying the most promising candidates, and further optimizing and the leading series as we work toward IND enabling studies. Let us now move to our second program in the agriculture chemical sector through our subsidiary at Planus. Earlier this week, Act Planus announced significant progress in two fungicide discovery programs targeting novel modes of action against septoria, one of the most economically significant diseases affecting wheat production, mainly in Europe. According to the published data, historically, more than 70% of fungicides used in European wheat production has been directed toward controlling this disease, representing An estimated market opportunity of approximately 1.2 billion euro. One of the key challenges in this market is the growing resistance of fungal pathogens to existing fungicides, particularly widely used fungicide classes such as SDHIS. This highlights the need for new solutions based on different mode of actions that could provide effective alternatives as existing treatments becomes less effective. This is precisely the opportunity that ACK Planus discovery programs are designed to address. In this program, ActPlanus is focusing on two proteins that are essential for fungal survival and have not previously been exploited as targets for commercial fungicide development. These targets were identified using the company's proprietary computational model, TargetSelector, which incorporates and other biological validation systems to assess the essentiality of selected protein targets. Building on this work, Agplanus leveraged its KEMPASS-AI for-Ag platform to design and generate active molecules targeting both proteins. Biological evaluations have demonstrated promising results. The identified molecules not only inhibit their intended fungal protein targets, but also exhibit fungicide activity, including against septoria strains that have developed resistance to existing fungicides. Plantissue demonstrated a 75% reduction in disease severity compared to the untreated control. Importantly, some of these biological findings have also been independently validated by an external research organization, providing additional confidence in the results and supporting the continued advancement of both programs. In addition to Septoria, Our evaluations have identified activity against other fungal pathogens, suggesting potential applications across a broader range of fungal diseases and opportunities to expand the commercial potential of certain molecules. Overall, we believe this finding represents an important milestone in aclinose They demonstrate the potential of our computational discovery capabilities to develop molecules with novel mode of action, addressing one of the major challenges in modern crop protections, the growing resistance of fungal pathogens to existing fungicides. Our next step will focus on molecular optimizations, expanded biological testing, and advancing the most promising candidates to Greenhouse and substantially Fieldwise. Initial discussions have revealed strong interest among potential partners in innovative sectorial solutions based on novel mode of action. We look forward to exploring collaboration opportunities over the coming year to accelerate development and enhance the program's commercial potential. This slide presents the company's overall activity, including its collaborations portfolio, while today's discussion has focused specifically on our internal development programs. I believe that the two programs we present today clearly demonstrate Evogen's strategy of building an independent pipeline of products candidates based on small molecules. On the pharmaceutical side, We are advancing an internal development therapeutic assets in an area of significant medical need, leveraging the molecular discovery capabilities of campus AI. On the agriculture side, through AgPlanus, we are applying similar technological capabilities to develop In both cases, our objective is to translate the company's technological and scientific advantages into proprietary assets with significant commercial potential. We believe that the progress presented today provides an important foundation for the continued development of these programs and for creating value for the company and its shareholders. I would now like to hand over the discussion to Ms. Polina Ravzin, the company's VP Finance, who will present Evogen's financial results for the third quarter of 2026. Polina, over to you.
Polina Ravzin
VP Finance
Thank you, Ofer. I will now walk you through Evogen's financial results for the first nine months and the third quarter of 2026. I will start with our cash position. As of September 30, 2026, Evogen held consolidated cash, cash equivalents, and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a directors' and officers' insurance payment of approximately $0.5 million covering an 18-month period. Revenues for the 9 months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to a lower revenue recognized by Castera, which in the first half of 2025 included significant seed sales of approximately $2 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026. Research and development expenses net of non-refundable grants for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million and increased from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately 0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuation of the US dollar-shekel exchange rate between the periods. Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million compared to approximately $0.4 million in the third quarter of 2025, primarily due to the lower sales and marketing expenses at Castera and at Plens. General and administrative expenses for the nine months of ended September 30, 2026 decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general administrative expenses across Avogen and its subsidiaries was largely offset mainly by transaction costs associated with the Warrant Inducement Transaction and additional non-recurrent legal expenses related to the corporate governance and the shareholders' matters. These costs totaled approximately $0.4 million and $0.3 million during the 9-month and 3-month periods ended September 30, 2026, respectively. Financing expenses net for the 9 months of 2026 were approximately $1.6 million, compared to the financing income net of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 Warrant Inducement Transaction, the company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income net was approximately $176,000 compared to approximately $79,000 in the corresponding period of 2025 with no material change between the periods. Loss from discontinued operations net for the 9 months of 2026 was approximately $0.5 million compared to an income from discontinued operations net of approximately $4 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Levy BIOS and Biomekas operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single line item in the consolidated statements of Profit and Loss. Following the sale of the majority of Levy Bios assets as well as Evogen's MicroBoost AI for Ag to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Levy Bios and Biomica's operating expenses levels had decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Levy Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025. Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICAL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICAL transaction during the third quarter of 2025 as discussed above. This concludes my review of our financial results. I will now turn the call back over to the operator.
Conference Operator
Operator
Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. In order to send the question, use the chat button located at the bottom of your screen.
Conference Operator
Operator
Please type your full name and your company's name before the question.
Conference Operator
Operator
The first question from Scott Henry, AGP. When would you expect to out-license or partner your pharmaceutical compounds? How does the timeline from compound selection to clinic files differ between pharma and agricultural compounds? Was there any movement between stages for the disclosed pipeline during third quarter of 2026?
Ofer Haviv
President and CEO
Hi, this is Ofer, can you hear me?
Conference Operator
Operator
Yes, Ofer, we can hear you.
Ofer Haviv
President and CEO
Oh, thank you. So, with respect to the first question, I think that our internal program that we discussed today in detail is nicely advanced, and we are just now in the stage where we start to receive the novel compounds from the synthesis and we are planning to validate them here in Israel but also in the lab of the professor that is part from our advisory board in this program and we expect to be able to enter into preclinical trial probably during mid next year I think this will be the time that then we can start to approach a pharma company with the results that we will gather until this point of time and on the initial results that we start to receive from the preclinical trial. And since this area, there are not too many companies like Evogen focusing on, In the other hand, there are a few pharma companies that are interested in this type of product. I really hope to see high interest, even though it's still in the early stage. I think this will be an interesting point where the work that we conduct will be judged by a pharma company. I think also the fact that we are using these two advisors in this specific program, which they are a world leader's opinion, I think this is very important in our efforts also to commercialize those compounds when we get to this specific point in time. The second part is what is the difference between ag and pharma? So I think the big difference is the confidence you have when you enter into the regulatory phase, which in human you start this stage very early in the process because you cannot validate your compounds on human without the FDA approval. to even to start the validation. While in ag, you can start the validation on crop without any regulatory approval except for research level, which this is not a major issue to receive this type of approval. So when you start to the full regulatory stage, actually, you know that you have a product because you made most of the validation earlier. So, from time perspective, the gap is not huge, but the information you have when you enter into the more critical phase and more expensive phase in ag, the level of confidence is much higher compared to human. In a way, what we are planning to do in the program for Septoria that we discussed today, We are planning to start the validation of the leading compound on crop, maybe first at the greenhouse and later on in field trial, probably next year, which this is something that I can't say that we are going to do in our pharma program, meaning to validate the compounds on human, which is the equivalent to what just now said that we are going to validate it in wheat, in greenhouse and field trial. The third part of the question is if we are advancing in our pipeline in the different collaboration that we engage and we disclosed in the past. So today I prefer to focus on the internal program, the program that we are managing and funding 100% by ourselves. There are advancements in the program that we are conducting with collaboration. We are going to release the complete presentation soon. Every quarter we release an update presentation where we disclose the current status of our pipeline. So I think that the information will be there. and I can say that almost every month we get more and more results from our partners that strengthens our confidence on the quality of our platform and my planning is that in the next analyst goal to focus a lot on the ongoing collaboration and collaboration agreement and the I repeat, if you have a question, please send it by the chat button located at the bottom of the screen. Please type your full name and your company's name before the question.
Conference Operator
Operator
There are no further questions at this time. Mr. Haviv, would you like to make a concluding statement?
Ofer Haviv
President and CEO
Yes, thank you. I would like to thank everybody for participating in this analyst call. Feel free to contact me if you have any additional questions. I'm always available and I'm looking forward to continue to update you on the future progress of Evogen. Thank you very much.
Conference Operator
Operator
Thank you. This concludes Evogen's third quarter 2026 results conference call. Thank you for your participation. You may go ahead and disconnect.